Riverbridge Partners LLC Lowers Stock Position in Charles River Laboratories International, Inc. $CRL

Riverbridge Partners LLC trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 35.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,788 shares of the medical research company’s stock after selling 35,540 shares during the quarter. Riverbridge Partners LLC’s holdings in Charles River Laboratories International were worth $11,003,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in Charles River Laboratories International by 14.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after buying an additional 40,073 shares during the period. National Bank of Canada FI lifted its position in shares of Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after acquiring an additional 511,901 shares in the last quarter. Gotham Asset Management LLC lifted its position in shares of Charles River Laboratories International by 17.3% in the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock valued at $49,403,000 after acquiring an additional 46,594 shares in the last quarter. Contravisory Investment Management Inc. bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $1,223,000. Finally, Nordea Investment Management AB grew its position in shares of Charles River Laboratories International by 43.6% during the fourth quarter. Nordea Investment Management AB now owns 54,694 shares of the medical research company’s stock worth $10,985,000 after purchasing an additional 16,616 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL stock opened at $186.08 on Wednesday. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $228.88. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a fifty day simple moving average of $175.14 and a two-hundred day simple moving average of $182.81. The firm has a market capitalization of $8.96 billion, a P/E ratio of -49.49, a price-to-earnings-growth ratio of 2.07 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same period last year, the company posted $2.34 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent analyst reports. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price on the stock. Barclays increased their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Morgan Stanley upgraded shares of Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $185.00 to $220.00 in a research report on Wednesday, June 17th. Evercore reissued an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Finally, CLSA upgraded shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their target price for the stock from $167.00 to $219.00 in a research report on Friday, May 29th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.